Cargando…
Myelomatous effusion with poor response to chemotherapy.
While pleural effusion in multiple myeloma is relatively infrequent, myelomatous pleural effusion is extremely rare. We experienced a 61-year-old woman with IgD-lambda multiple myeloma and pleural effusion. The diagnosis was made originally by pleural biopsy, pleural fluid cytology and immunoelectro...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Korean Academy of Medical Sciences
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3054621/ https://www.ncbi.nlm.nih.gov/pubmed/10803706 |
_version_ | 1782199990328754176 |
---|---|
author | Kim, Y. M. Lee, K. K. Oh, H. S. Park, S. K. Won, J. H. Hong, D. S. Park, H. S. Park, J. S. Lee, D. W. |
author_facet | Kim, Y. M. Lee, K. K. Oh, H. S. Park, S. K. Won, J. H. Hong, D. S. Park, H. S. Park, J. S. Lee, D. W. |
author_sort | Kim, Y. M. |
collection | PubMed |
description | While pleural effusion in multiple myeloma is relatively infrequent, myelomatous pleural effusion is extremely rare. We experienced a 61-year-old woman with IgD-lambda multiple myeloma and pleural effusion. The diagnosis was made originally by pleural biopsy, pleural fluid cytology and immunoelectropheresis of pleural fluid. Transient improvement of the pleural effusion was observed after administration of combination chemotherapy of vincristine, melphalan, cyclophosphamide, prednisone (VMCP)/vincristine, cyclophosphamide, adriamycin, prednisone (VCAP). Two months later, myelomatous pleural effusion recurred and no response to salvage therapy was observed. We reviewed the clinical feature of this case and literature concerning myelomatous pleural effusion. |
format | Text |
id | pubmed-3054621 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2000 |
publisher | Korean Academy of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-30546212011-03-15 Myelomatous effusion with poor response to chemotherapy. Kim, Y. M. Lee, K. K. Oh, H. S. Park, S. K. Won, J. H. Hong, D. S. Park, H. S. Park, J. S. Lee, D. W. J Korean Med Sci Research Article While pleural effusion in multiple myeloma is relatively infrequent, myelomatous pleural effusion is extremely rare. We experienced a 61-year-old woman with IgD-lambda multiple myeloma and pleural effusion. The diagnosis was made originally by pleural biopsy, pleural fluid cytology and immunoelectropheresis of pleural fluid. Transient improvement of the pleural effusion was observed after administration of combination chemotherapy of vincristine, melphalan, cyclophosphamide, prednisone (VMCP)/vincristine, cyclophosphamide, adriamycin, prednisone (VCAP). Two months later, myelomatous pleural effusion recurred and no response to salvage therapy was observed. We reviewed the clinical feature of this case and literature concerning myelomatous pleural effusion. Korean Academy of Medical Sciences 2000-04 /pmc/articles/PMC3054621/ /pubmed/10803706 Text en |
spellingShingle | Research Article Kim, Y. M. Lee, K. K. Oh, H. S. Park, S. K. Won, J. H. Hong, D. S. Park, H. S. Park, J. S. Lee, D. W. Myelomatous effusion with poor response to chemotherapy. |
title | Myelomatous effusion with poor response to chemotherapy. |
title_full | Myelomatous effusion with poor response to chemotherapy. |
title_fullStr | Myelomatous effusion with poor response to chemotherapy. |
title_full_unstemmed | Myelomatous effusion with poor response to chemotherapy. |
title_short | Myelomatous effusion with poor response to chemotherapy. |
title_sort | myelomatous effusion with poor response to chemotherapy. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3054621/ https://www.ncbi.nlm.nih.gov/pubmed/10803706 |
work_keys_str_mv | AT kimym myelomatouseffusionwithpoorresponsetochemotherapy AT leekk myelomatouseffusionwithpoorresponsetochemotherapy AT ohhs myelomatouseffusionwithpoorresponsetochemotherapy AT parksk myelomatouseffusionwithpoorresponsetochemotherapy AT wonjh myelomatouseffusionwithpoorresponsetochemotherapy AT hongds myelomatouseffusionwithpoorresponsetochemotherapy AT parkhs myelomatouseffusionwithpoorresponsetochemotherapy AT parkjs myelomatouseffusionwithpoorresponsetochemotherapy AT leedw myelomatouseffusionwithpoorresponsetochemotherapy |